Shares of Baudax Bio
BXRX,
jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech developing Treg-based cell therapies for autoimmune diseases. TeraImmune has a cell therapy candidate to eliminate certain clotting factor inhibitors in patients with hemophilia A, a rare genetic bleeding disorder, Baudax said in a release. All TeraImmune outstanding equity interests were exchanged for a combination of Baudax shares and newly designated non-voting convertible preferred stock, Baudax said.
